GLP-1 medications have transformed diabetes and obesity care, while telehealth has made these treatments easier to access. However, offering GLP-1 treatment online today involves more than connecting patients with prescribers. Providers and businesses must consider federal drug-compounding rules, state telehealth requirements, prescribing practices, advertising claims, and patient-safety procedures.
Understanding these obligations can help telehealth organizations reduce regulatory risk and create safer processes and clearer care for patients receiving semaglutide, tirzepatide, or other GLP-1 medications. Continue reading to learn more.
Understanding the Compliance Framework
GLP-1 Telehealth Compliance: Key Considerations for Providers
Telehealth providers should first determine which parts of their business involve medical practice, prescribing, dispensing, compounding, or marketing. Each activity may be governed by different federal and state requirements.
This is particularly important when a company works with a compounding pharmacy rather than dispensing an FDA-approved product. Compounded medications are prepared for specific circumstances and are not FDA-approved. Under federal law, Sections 503A and 503B establish different pathways for drug compounding:
-
- 503A: Generally applies to state-licensed pharmacies or physicians compounding medications for individual patients with prescriptions.
- 503B: Applies to FDA-registered outsourcing facilities and includes additional requirements.
The distinction matters because a business cannot assume that every compounded GLP-1 product can legally be prepared or marketed.
When Legal Review Can Help
Because GLP-1 programs can involve multiple laws and business relationships, providers may benefit from professional review before launching or changing their services. GLP-1 Legal Compliance Specialists can help organizations:
- Assess their overall business model
- Identify applicable federal and state requirements
- Review advertising and promotional claims
- Examine telehealth prescribing procedures
- Identify potential issues involving pharmacy relationships
- Develop processes for documenting and addressing compliance concerns
Depending on the organization’s needs, this work may involve healthcare attorneys, regulatory counsel, or compliance consultants familiar with GLP-1 services.
Telehealth Prescribing Requirements
Providers should verify that their prescribing practices comply with the rules in each state where they treat patients. Depending on the jurisdiction and business model, this may involve:
- Clinician licensing requirements
- Patient evaluation and assessment
- Medical recordkeeping
- Informed consent
- Appropriate prescribing relationships
- Follow-up and monitoring
Businesses should also establish who is responsible for clinical decisions. A telehealth company should clearly distinguish the roles of its:
- Technology platform
- Healthcare providers
- Pharmacy partners
- Other service providers
Written procedures can help ensure that patients receive appropriate evaluation, prescriptions, instructions, and follow-up.
Compounded GLP-1s and Patient Safety
Compounded GLP-1 medications require particular attention because their formulations, concentrations, packaging, and instructions can differ from FDA-approved products. FDA has reported dosing errors involving compounded semaglutide, including situations where patients measured incorrect amounts or healthcare professionals miscalculated doses.
Providers should, as a result, review:
- Product concentration
- Medication labeling
- Storage instructions
- Administration directions
- Dose-escalation instructions
- Patient counseling materials
Staff should also have a clear process for answering dosing questions and escalating suspected adverse events.
Advertising and Marketing
Marketing is another important compliance area. Telehealth companies should ensure that promotional materials do not:
- Describe compounded medications as FDA-approved
- Present compounded products as identical to FDA-approved medications
- Make unsupported claims about safety or effectiveness
- Misrepresent the product’s ingredients or source
Marketing claims should be accurate and appropriately supported.
This issue has received significant regulatory attention. In March 2026, the FDA announced that it had issued warning letters to 30 telehealth companies over misleading claims about compounded GLP-1 products. This demonstrates why marketing materials deserve the same compliance attention as prescribing and dispensing workflows.
Endnote
GLP-1 telehealth programs operate in a rapidly changing regulatory environment. Providers should review current federal and state requirements before offering compounded medications, changing prescribing practices, or launching new marketing campaigns. Professional legal and regulatory guidance can help identify risks that may not be obvious during routine operations. Compliance should ultimately support both lawful business practices and safer, clearer care for patients using GLP-1 medications.